If you read my post #3895, you'll see that I make the case
If you read my post #3895, you'll see that I make the case that a R/S isn't a bad thing in itself. What needs to happen is the authorized shares needs to decrease at the same time as a R/S.
This in my opinion was the only part of the proxy that I disagree. They will have my vote on all items if they change the R/S vote so that authorized shares are reduced by the same ratio.
A R/S after a commercial contract is announced can be a good thing to get us to the NASDAQ quickly where institutional investors and many other solid investors trade the market. I think that we will easily hit $1 on the OTC on sales announcement, but the sulking trading schemes of OTC market makers and day traders could hinder continued growth.
1
Quantum Materials Corp. (QTMM) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Hyzon Motors Announces Delisting from Nasdaq Hyzon Motors Inc. is making a significant shift regarding its stock trading status. This U.S. company, known for its commitment to high-performance hydrogen fuel cell technology, has decided to inform Nasdaq Stock Market of its intent to delist its Class A common stock and publicly traded warrants. This move comes as part of...
Continue Reading
Your Gateway to High Returns in Crypto Staking As the digital currency landscape continues to expand, platforms like Keynode.net are leading the charge in offering unprecedented opportunities for investors. For those seeking impressive annual percentage yields (APY) through crypto staking, Keynode.net has emerged as a premier choice. Its user-friendly interface, robust...
Continue Reading
Overview of the Class Action Lawsuit Against Rocket Pharmaceuticals Pomerantz LLP has initiated a class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) highlighting various concerns regarding the company's business practices. Investors who have suffered losses during the stipulated Class Period should take note of this unfolding situation. Key Details...
Continue Reading
Revitalizing Economic Growth at the 23rd SMDO Conference The 23rd Annual South Metro Development Outlook (SMDO25) Conference stands as a pivotal forum for industry leaders, policymakers, and community stakeholders. It is designed to foster collaboration and tackle some of the most pressing issues faced by the region today. Set against the backdrop of changing federal...
Continue Reading
Strong First Quarter Results for SciBase In the recent interim report, SciBase has showcased an impressive performance for the first quarter of 2025. The medical technology company, renowned for its innovative dermatological solutions, recorded net sales of TSEK 8,856, marking a remarkable increase of 46% from the previous year’s figures. Financial Performance Overview...
Continue Reading
